141 related articles for article (PubMed ID: 10770781)
1. MICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animals.
Bowersock TL; Salmon SA; Portis ES; Prescott JF; Robison DA; Ford CW; Watts JL
Antimicrob Agents Chemother; 2000 May; 44(5):1367-9. PubMed ID: 10770781
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions.
Shinabarger DL; Marotti KR; Murray RW; Lin AH; Melchior EP; Swaney SM; Dunyak DS; Demyan WF; Buysse JM
Antimicrob Agents Chemother; 1997 Oct; 41(10):2132-6. PubMed ID: 9333037
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
D'Andrea S; Zheng ZB; Denbleyker K; Fung-Tomc JC; Yang H; Clark J; Taylor D; Bronson J
Bioorg Med Chem Lett; 2005 Jun; 15(11):2834-9. PubMed ID: 15911264
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae.
Mason EO; Lamberth LB; Kaplan SL
Antimicrob Agents Chemother; 1996 Apr; 40(4):1039-40. PubMed ID: 8849225
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori.
Hirschl AM; Apfalter P; Makristathis A; Rotter ML; Wimmer M
Antimicrob Agents Chemother; 2000 Jul; 44(7):1977-9. PubMed ID: 10858365
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
Rybak MJ; Cappelletty DM; Moldovan T; Aeschlimann JR; Kaatz GW
Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
[TBL] [Abstract][Full Text] [Related]
7. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials.
Dresser LD; Rybak MJ
Pharmacotherapy; 1998; 18(3):456-62. PubMed ID: 9620097
[TBL] [Abstract][Full Text] [Related]
8. Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium.
Schülin T; Thauvin-Eliopoulos C; Moellering RC; Eliopoulos GM
Antimicrob Agents Chemother; 1999 Dec; 43(12):2873-6. PubMed ID: 10582874
[TBL] [Abstract][Full Text] [Related]
9. Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents.
Biedenbach DJ; Jones RN
J Clin Microbiol; 1997 Dec; 35(12):3198-202. PubMed ID: 9399519
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility testing of linezolid by two standard methods.
Hamilton-Miller JM; Shah S
Eur J Clin Microbiol Infect Dis; 1999 Mar; 18(3):225-7. PubMed ID: 10357061
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of the oxazolidinone compounds linezolid (PNU-100766) and eperzolid (PNU-100592) against middle ear isolates of Streptococcus pneumoniae.
Kearney JA; Barbadora K; Mason EO; Wald ER; Green M
Int J Antimicrob Agents; 1999 Jul; 12(2):141-4. PubMed ID: 10418759
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities in new oxazolidinone antimicrobial agents against enterococci.
Eliopoulos GM; Wennersten CB; Gold HS; Moellering RC
Antimicrob Agents Chemother; 1996 Jul; 40(7):1745-7. PubMed ID: 8807077
[TBL] [Abstract][Full Text] [Related]
13. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.
Johnson AP; Warner M; Livermore DM
J Antimicrob Chemother; 2000 Feb; 45(2):225-30. PubMed ID: 10660506
[TBL] [Abstract][Full Text] [Related]
14. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.
Cynamon MH; Klemens SP; Sharpe CA; Chase S
Antimicrob Agents Chemother; 1999 May; 43(5):1189-91. PubMed ID: 10223934
[TBL] [Abstract][Full Text] [Related]
15. Relapsing Rhodococcus equi infection in a heart transplant recipient successfully treated with long-term linezolid.
Muñoz P; Palomo J; Guinea J; Yañez J; Giannella M; Bouza E
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):197-9. PubMed ID: 17949934
[TBL] [Abstract][Full Text] [Related]
16. The discovery of linezolid, the first oxazolidinone antibacterial agent.
Ford CW; Zurenko GE; Barbachyn MR
Curr Drug Targets Infect Disord; 2001 Aug; 1(2):181-99. PubMed ID: 12455414
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.
Noskin GA; Siddiqui F; Stosor V; Hacek D; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2059-62. PubMed ID: 10428937
[TBL] [Abstract][Full Text] [Related]
18. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
von Eiff C; Peters G
J Antimicrob Chemother; 1999 Apr; 43(4):569-73. PubMed ID: 10350389
[TBL] [Abstract][Full Text] [Related]
19. The in-vitro activity of linezolid (U-100766) and tentative breakpoints.
Wise R; Andrews JM; Boswell FJ; Ashby JP
J Antimicrob Chemother; 1998 Dec; 42(6):721-8. PubMed ID: 10052894
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.
Jorgensen JH; McElmeel ML; Trippy CW
Antimicrob Agents Chemother; 1997 Feb; 41(2):465-7. PubMed ID: 9021209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
